1. Introduction
1.1 Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Market Insights
2.2 Market Attractiveness
3. Research Methodology
3.1 Secondary Research
3.2 Primary Research
- 3.2.1 Data Triangulation and Validation
4. Europe Carbapenem-Based Antibiotics Market Landscape
4.1 Overview
4.3 Ecosystem Analysis
- 4.3.1 List of Vendors in the Value Chain
5. Europe Carbapenem-Based Antibiotics Market – Key Market Dynamics
5.1 Market Drivers
5.2 Market Restraints
5.3 Market Opportunities
5.4 Future Trends
5.5 Impact of Drivers and Restraints
6. Europe Carbapenem-Based Antibiotics Market Regional Analysis
6.2 Europe Carbapenem-Based Antibiotics Market Revenue 2019-2028 (US$ Million)
6.3 Europe Carbapenem-Based Antibiotics Market Forecast Analysis
7. Europe Carbapenem-Based Antibiotics Market Analysis – by Type
7.1 Meropenem
- 7.1.1 Overview
- 7.1.2 Meropenem: Europe Carbapenem-Based Antibiotics Market – Revenue and Forecast, 2019-2028 (US$ Million)
7.2 Doripenem
- 7.2.1 Overview
- 7.2.2 Doripenem: Europe Carbapenem-Based Antibiotics Market – Revenue and Forecast, 2019-2028 (US$ Million)
7.3 Imipenem
- 7.3.1 Overview
- 7.3.2 Imipenem: Europe Carbapenem-Based Antibiotics Market – Revenue and Forecast, 2019-2028 (US$ Million)
7.4 Tebipenem
- 7.4.1 Overview
- 7.4.2 Tebipenem: Europe Carbapenem-Based Antibiotics Market – Revenue and Forecast, 2019-2028 (US$ Million)
8. Europe Carbapenem-Based Antibiotics Market Analysis – by Indication
8.1 Bacterial Meningitis
- 8.1.1 Overview
- 8.1.2 Bacterial Meningitis: Europe Carbapenem-Based Antibiotics Market – Revenue and Forecast, 2019-2028 (US$ Million)
8.2 Acute Pelvic Infections
- 8.2.1 Overview
- 8.2.2 Acute Pelvic Infections: Europe Carbapenem-Based Antibiotics Market – Revenue and Forecast, 2019-2028 (US$ Million)
8.3 Respiratory Tract Infections
- 8.3.1 Overview
- 8.3.2 Respiratory Tract Infections: Europe Carbapenem-Based Antibiotics Market – Revenue and Forecast, 2019-2028 (US$ Million)
8.4 Intra-Abdominal Infections
- 8.4.1 Overview
- 8.4.2 Intra-Abdominal Infections: Europe Carbapenem-Based Antibiotics Market – Revenue and Forecast, 2019-2028 (US$ Million)
8.5 Urinary Tract Infections
- 8.5.1 Overview
- 8.5.2 Urinary Tract Infections: Europe Carbapenem-Based Antibiotics Market – Revenue and Forecast, 2019-2028 (US$ Million)
9. Europe Carbapenem-Based Antibiotics Market Analysis – by Distribution Channel
9.1 Retail Pharmacies
- 9.1.1 Overview
- 9.1.2 Retail Pharmacies: Europe Carbapenem-Based Antibiotics Market – Revenue and Forecast, 2019-2028 (US$ Million)
9.2 Online Pharmacies
- 9.2.1 Overview
- 9.2.2 Online Pharmacies: Europe Carbapenem-Based Antibiotics Market – Revenue and Forecast, 2019-2028 (US$ Million)
9.3 Hospital Pharmacies
- 9.3.1 Overview
- 9.3.2 Hospital Pharmacies : Europe Carbapenem-Based Antibiotics Market – Revenue and Forecast, 2019-2028 (US$ Million)
10. Europe Carbapenem-Based Antibiotics Market – Europe Analysis
10.1 Overview
10.2 Europe
- 10.2.1 Europe Carbapenem-Based Antibiotics Market Breakdown, by Key
Country, 2022 and 2028 (%)
- 10.2.1.1 Europe Carbapenem-Based Antibiotics Market – Revenue and
Forecast Analysis – by Country
- 10.2.1.1 UK:
Europe Carbapenem-Based Antibiotics Market – Revenue and Forecast to 2028 (US$ Million)
- 10.2.1.1.1 UK: Europe Carbapenem-Based Antibiotics Market Breakdown, by Type
- 10.2.1.1.2 UK: Europe Carbapenem-Based Antibiotics Market Breakdown, by Indication
- 10.2.1.1.3 UK: Europe Carbapenem-Based Antibiotics Market Breakdown, by Distribution Channel
- 10.2.1.2 Germany:
Europe Carbapenem-Based Antibiotics Market – Revenue and Forecast to 2028 (US$ Million)
- 10.2.1.2.1 Germany: Europe Carbapenem-Based Antibiotics Market Breakdown, by Type
- 10.2.1.2.2 Germany: Europe Carbapenem-Based Antibiotics Market Breakdown, by Indication
- 10.2.1.2.3 Germany: Europe Carbapenem-Based Antibiotics Market Breakdown, by Distribution Channel
- 10.2.1.3 France:
Europe Carbapenem-Based Antibiotics Market – Revenue and Forecast to 2028 (US$ Million)
- 10.2.1.3.1 France: Europe Carbapenem-Based Antibiotics Market Breakdown, by Type
- 10.2.1.3.2 France: Europe Carbapenem-Based Antibiotics Market Breakdown, by Indication
- 10.2.1.3.3 France: Europe Carbapenem-Based Antibiotics Market Breakdown, by Distribution Channel
- 10.2.1.4 Russia:
Europe Carbapenem-Based Antibiotics Market – Revenue and Forecast to 2028 (US$ Million)
- 10.2.1.4.1 Russia: Europe Carbapenem-Based Antibiotics Market Breakdown, by Type
- 10.2.1.4.2 Russia: Europe Carbapenem-Based Antibiotics Market Breakdown, by Indication
- 10.2.1.4.3 Russia: Europe Carbapenem-Based Antibiotics Market Breakdown, by Distribution Channel
- 10.2.1.5 Italy:
Europe Carbapenem-Based Antibiotics Market – Revenue and Forecast to 2028 (US$ Million)
- 10.2.1.5.1 Italy: Europe Carbapenem-Based Antibiotics Market Breakdown, by Type
- 10.2.1.5.2 Italy: Europe Carbapenem-Based Antibiotics Market Breakdown, by Indication
- 10.2.1.5.3 Italy: Europe Carbapenem-Based Antibiotics Market Breakdown, by Distribution Channel
- 10.2.1.6 Rest of Europe:
Europe Carbapenem-Based Antibiotics Market – Revenue and Forecast to 2028 (US$ Million)
- 10.2.1.6.1 Rest of Europe: Europe Carbapenem-Based Antibiotics Market Breakdown, by Type
- 10.2.1.6.2 Rest of Europe: Europe Carbapenem-Based Antibiotics Market Breakdown, by Indication
- 10.2.1.6.3 Rest of Europe: Europe Carbapenem-Based Antibiotics Market Breakdown, by Distribution Channel
11. Competitive Landscape
11.1 Heat Map Analysis
11.2 Company Positioning and Concentration
12. Industry Landscape
12.1 Overview
12.2 Market Initiative
12.3 Partnerships and Collaborations
12.4 Other Developments
13. Company Profiles
13.1 ACS Dobfar S.p.A
- 13.1.1 Key Facts
- 13.1.2 Business Description
- 13.1.3 Products and Services
- 13.1.4 Financial Overview
- 13.1.5 SWOT Analysis
- 13.1.6 Key Developments
13.2 Iterum Therapeutics plc
- 13.2.1 Key Facts
- 13.2.2 Business Description
- 13.2.3 Products and Services
- 13.2.4 Financial Overview
- 13.2.5 SWOT Analysis
- 13.2.6 Key Developments
13.3 DAEWOONG PHARMACEUTICAL CO., LTD
- 13.3.1 Key Facts
- 13.3.2 Business Description
- 13.3.3 Products and Services
- 13.3.4 Financial Overview
- 13.3.5 SWOT Analysis
- 13.3.6 Key Developments
13.4 Aurobindo Pharma Ltd
- 13.4.1 Key Facts
- 13.4.2 Business Description
- 13.4.3 Products and Services
- 13.4.4 Financial Overview
- 13.4.5 SWOT Analysis
- 13.4.6 Key Developments
13.5 Gland Pharma Limited
- 13.5.1 Key Facts
- 13.5.2 Business Description
- 13.5.3 Products and Services
- 13.5.4 Financial Overview
- 13.5.5 SWOT Analysis
- 13.5.6 Key Developments
13.6 Merck & Co., Inc.
- 13.6.1 Key Facts
- 13.6.2 Business Description
- 13.6.3 Products and Services
- 13.6.4 Financial Overview
- 13.6.5 SWOT Analysis
- 13.6.6 Key Developments
13.7 Sumitomo Dainippon Pharma Co., Ltd.
- 13.7.1 Key Facts
- 13.7.2 Business Description
- 13.7.3 Products and Services
- 13.7.4 Financial Overview
- 13.7.5 SWOT Analysis
- 13.7.6 Key Developments
13.8 Savior Lifetec
- 13.8.1 Key Facts
- 13.8.2 Business Description
- 13.8.3 Products and Services
- 13.8.4 Financial Overview
- 13.8.5 SWOT Analysis
- 13.8.6 Key Developments
13.9 Pfizer Inc.
- 13.9.1 Key Facts
- 13.9.2 Business Description
- 13.9.3 Products and Services
- 13.9.4 Financial Overview
- 13.9.5 SWOT Analysis
- 13.9.6 Key Developments
13.10 Spero Therapeutics
- 13.10.1 Key Facts
- 13.10.2 Business Description
- 13.10.3 Products and Services
- 13.10.4 Financial Overview
- 13.10.5 SWOT Analysis
- 13.10.6 Key Developments
14. Appendix
14.1 About Business Market Insights
14.2 List of Abbreviations